AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 22 min read$KYMR

Mainolfi Nello sold $9.2M of KYMR

Mainolfi Nello (Chief Executive Officer) sold 80,000 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $115.29 ($112.80–$116.56, $9.22M total) across 5 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mainolfi Nello
Published Jul 2, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KYMR
Neutral
medium confidence
Mentioned
$KYMR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$9.22M could slightly pressure sentiment, but the stated 10b5-1 plan suggests the trades were scheduled in advance.

02

Market read

This provides a fresh, primary-source datapoint on insider behavior, but it does not include operational or financial updates that would materially reset valuation expectations.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or financing news, the signal is mostly sentiment-level.

Relevance 5/10Novelty 5/10Timing: Filed July 2 after trades on July 1

Background

The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc. (KYMR).

Company-level read

Ticker impact

$KYMRNeutralMedium confidence
Context

Kymera Therapeutics CEO Mainolfi Nello sold 80,000 shares in open-market trades totaling about $9.22M under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be modest unless paired with other company-specific catalysts.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size ($9.22M) and role (CEO), but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens signal strength.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on Kymera’s prospects.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CEO sold 80,000 shares totaling ~$9.22M.

  • insider
    Mainolfi Nello

    CEO and director who executed the open-market sales under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$KYMRMed

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.

investingnews.com6 min
AUG 5
$KYMRMed

Kymera Therapeutics, Inc. (KYMR): Results of Operations and Financial Condition

Kymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data e

SEC EDGAR 8-K6 min
JUL 13
$AXPMed

American Express, Biogen upgraded: Wall Street's top analyst calls

Wall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).

yahoo.com4 min
JUL 13
$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

yahoo.com6 min